Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMA9M81)

Drug Name
CAR138 T Cells Drug Info
Indication
Disease Entry ICD 11 Status REF
Immune System disease 4A01-4B41 Phase 1 [1]
Multiple myeloma 2A83 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMA9M81

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Syndecan-1 (SDC1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BT-062 DMYO185 Multiple myeloma 2A83 Phase 2 [2]
CD138 CAR T cells DMCSGNU Multiple myeloma 2A83 Phase 1/2 [3]
CART-138 cells DMB4HEW Multiple myeloma 2A83 Phase 1/2 [4]
CART-138 cells DMB4HEW Multiple myeloma 2A83 Phase 1/2 [5]
CAR-T cells targeting CD138 DMHBQYU Multiple myeloma 2A83 Clinical trial [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Syndecan-1 (SDC1) TTYDSVG SDC1_HUMAN CAR-T-Cell-Therapy [1]

References

1 ClinicalTrials.gov (NCT03672318) Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
2 The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009 Jun 15;15(12):4028-37.
3 ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
4 ClinicalTrials.gov (NCT01886976) Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138
5 ClinicalTrials.gov (NCT03196414) Study of CART-138/BCMA Therapy for R/R Multiple Myeloma
6 ClinicalTrials.gov (NCT03473496) CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma